Efficacy and tolerability of add-on trospium chloride in patients with benign prostate syndrome and overactive bladder: A non-interventional trial showing use of flexible dosing

UroToday International Journal

Volumn 2, Issue 2, 2009, Pages

  Wiedemann, Andreas ^a   Neumann, Gerhard ^b   Neumeister, Claudia ^c   Kusche, Werner ^d   Schwantes, Ulrich ^c  

^a Witten University   (Germany)

^b Private Practice for Urology   (Germany)

^c Dr R Pfleger GmbH   (Germany)

^d ACRO Clinical Research Services GmbH   (Germany)

Author keywords

Receptor blocker; Overactive bladder; Prostate syndrome; Trospium chloride

Indexed keywords

EID: 67649336782     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: 10.3834/uij.1944-5784.2009.04.02     Document Type: Article

References (15)

1. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/ lower urinary tract symptoms: an overview for the practicing clinician. BJU Int. 2004;94(5):738-744.
2. Andersson, K-E. Treatment of the overactive bladder syndrome and detrusor overactivity with antimuscarinic drugs. Continence. 2005;1:1-8.
3. Saito H, Yamada T, Oshima H et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and in combination of propiverine hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999;8:525-536.
4. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169(6):2253-2256.
5. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94(6):817-820.
6. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3):999-1004.
7. BfArM. Empfehlung zur Planung und Durchführung von Anwendungs-beobachtungen. Banz. 1998;229:16884-5.
8. Athanasopoulos A, Perimenis P. Efficacy of the combination of an α1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother. 2005;6(14):2429-2433.
9. Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary ract symptoms: a systematic review. Europ Urol. 2006;50(4):675-683.
10. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan, Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA. 2006;296:2319-28.
11. Oelke M, Höfner K, Berges RR, Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results. Urologe A. 2002;41(5):425-441.
12. Rovner ES. Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother. 2005;6(4): 653-666.
13. Kamimura H, Oishi S, Matsushima H, et al. Identification of cytochrome P450 Isoenzymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998:28(10):909-922.
14. MacDiarmid SA. Maximizing anticholinergic therapy for overactive bladder. Has the ceiling been reached? Brit J Urol Int. 2007:99(3):8-12.
15. Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder. The issue of treatment tolerability. Am J Med. 2006:119(3A):9S-15S.